July 2026 Biotech Catalysts to Watch
FDA decisions and clinical trial readouts expected in July 2026, each marked with what — if anything — a primary source confirms about it.
No date on this page has been confirmed against a primary source. Unsourced entries are AI-drafted from public information and can be wrong about whether an event is still upcoming; they are listed separately and show the expected window only. Verify against the FDA, the company, or ClinicalTrials.gov before acting on any of them. 2 of 6 link to the ClinicalTrials.gov record for the program behind them — the registry confirms that the program exists, not the date.
6 catalysts shown
Phase 3 SKYSCRAPER-01 OS update for tiragolumab in NSCLC
Tiragolumab · First-line PD-L1 high NSCLC
Program confirmed on ClinicalTrials.gov · 2026-09-05 · the date itself is unverified
Sponsor record: 145 of 1045 late-stage studies registered by Roche were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
Roche's TIGIT inhibitor tiragolumab gets a final overall survival readout in lung cancer after multiple prior misses across the TIGIT class. A positive OS result would be a major comeback for TIGIT as an immuno-oncology mechanism.
TIGIT class has had repeated setbacks (Merck's vibostolimab, Gilead's domvanalimab). Probability of OS hit is low (~25-30%). A positive result reopens TIGIT investment across the sector.
AI-drafted context, not individually reviewed.
Phase 3 EVOLVE Phase 3 topline data for sepiapterin in PKU
Sepiapterin · Phenylketonuria (PKU)
Program confirmed on ClinicalTrials.gov · 2026-09-05 · the date itself is unverified
Sponsor record: 16 of 50 late-stage studies registered by PTC Therapeutics were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
PTC's oral BH4 precursor sepiapterin targets the BH4-responsive PKU population. Approval would establish a multi-hundred-million dollar franchise and validate PTC's strategic pivot after the Translarna setbacks.
Primary endpoint is phenylalanine reduction versus placebo. Phase 2 data was strong. A clean readout supports a 2026 NDA filing.
AI-drafted context, not individually reviewed.
Unconfirmed watchlist
No primary source has been found for these yet. They are AI-drafted from public information, shown with the expected window rather than a day, and may already have happened or moved. Treat them as prompts to check the company's guidance, not as dates.
[Superseded] UX111 in MPS IIIA (Sanfilippo A) — decision moved to September 19, 2026
UX111 (rebisufligene etisparvovec) · MPS IIIA / Sanfilippo syndrome type A
Unverified — date is AI-generated and has not been checked against a primary source.
Tight against cash. Cash reaches roughly Q1 2027 on the disclosed figures, about 2 quarters past this Q3 2026 catalyst. A disappointing result would leave little room to fund what comes next.
Sponsor record: 10 of 40 late-stage studies registered by Ultragenyx Pharmaceutical were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
Correction to this archived entry: no July 2026 decision occurred. The original UX111 BLA received a Complete Response Letter in July 2025 over manufacturing (CMC) issues; Ultragenyx resubmitted, the FDA accepted the new BLA in April 2026, and the action date is now September 19, 2026. See the September 2026 catalyst calendar for the current entry.
This entry is retained for the archive but superseded — the live UX111 decision is tracked on /catalyst/2026-09 with a September 19, 2026 PDUFA date.
AI-drafted context, not individually reviewed.
Phase 3 ARISE topline data for KarXT in Alzheimer's psychosis
Cobenfy (KarXT) · Alzheimer's-related psychosis
Unverified — date is AI-generated and has not been checked against a primary source.
Sponsor record: 114 of 689 late-stage studies registered by Bristol-Myers Squibb were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
BMY tests its Karuna acquisition Cobenfy in Alzheimer's psychosis. Acadia's Nuplazid failed the analogous trial; BMY's M1/M4 muscarinic mechanism is different. Approval would be a major new indication for the $14B Karuna acquisition.
Primary endpoint is psychosis symptom reduction at week 12. A clean win adds $2-4B in peak sales potential to Cobenfy and validates the Karuna deal. A miss puts pressure on BMY's neuro pipeline narrative.
AI-drafted context, not individually reviewed.
Phase 2 SOLSTICE topline data for tobevibart + elebsiran in chronic hepatitis B
Tobevibart + elebsiran combination · Chronic hepatitis B (functional cure)
Unverified — date is AI-generated and has not been checked against a primary source.
Sponsor record: 2 of 13 late-stage studies registered by Vir Biotechnology were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
Vir tests its combination siRNA + neutralizing antibody approach for functional cure of chronic hepatitis B. A meaningful functional cure rate would be transformative for a market with ~300M global patients and limited current options.
Functional cure rate (sustained HBsAg loss) versus standard of care. A cure rate above 25% would be a major positive signal. Most prior HBV cure programs have disappointed.
AI-drafted context, not individually reviewed.
Phase 2 topline data for tegavivint in CTNNB1-mutant solid tumors
Tegavivint · Beta-catenin mutant solid tumors
Unverified — date is AI-generated and has not been checked against a primary source.
Why it matters
Iterion's small molecule Wnt pathway inhibitor tegavivint reports its first meaningful efficacy readout in a precision-defined patient population. Beta-catenin mutations are a recognized resistance driver across multiple solid tumors with no approved targeted options.
Watch for objective response rate, disease control rate, and durability. Even modest activity in a defined biomarker population supports a Phase 3 pathway.
AI-drafted context, not individually reviewed.
Market context
July 2026 transitions biotech investors into the summer earnings season, with Q2 results expected in late July and early August. The catalyst slate is anchored by a heavy PDUFA week in early-to-mid July: Insmed's brensocatib decision (the single biggest small/mid-cap PDUFA of 2026), Mirum's volixibat in PFIC, Acadia's Daybue adult expansion, Ultragenyx's UX111 gene therapy in Sanfilippo A, and Travere's Filspari FSGS expansion. Late July adds two consequential mid-cap binary Phase 3 readouts: BMY's KarXT in Alzheimer's psychosis (a key test of the $14B Karuna acquisition) and PTC's sepiapterin in PKU. The macro backdrop continues the H1 2026 risk-on tone, though the market typically rotates defensively in July ahead of summer Q2 earnings. Large-cap names with subcutaneous immuno-oncology, oral GLP-1, and pipeline-driven defensive stories continue to outperform broad index returns. Small/mid-cap binary readouts offer the highest absolute alpha but require careful position sizing — INSM, RARE, BMY's KarXT extension, and TVTX all carry 30-50%+ stock-move potential in either direction.
Conferences this period
AAIC (Alzheimer's Association International Conference) 2026
July 25-30, 2026
IAS Conference on HIV Science 2026
July 19-23, 2026
Sponsored
Trade upcoming biotech catalysts commission-free on WebullAffiliate link — we may earn a commission at no cost to you
Want one of these readouts explained in writing?
Name a catalyst from this calendar and get a written breakdown of what the trial actually measures, what success and failure look like, and where the endpoint, safety, and financing risk sits — in 3 business days, for $249.
Get the free July 2026 catalyst briefing
Receive the next weekly briefing with the biggest upcoming catalysts, date changes, and plain-English context.
Free weekly biotech briefing. No spam. We only use this address for the briefing. By subscribing, you agree to our Privacy Policy and Terms.
No financial advice. Educational research only. Affiliate links may earn compensation.